A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.

about

A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.

Item

http://www.wikidata.org/entity/Q54922869

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

A phase II trial of 1st-line m ...... ng RAS mutation: JACCRO CC-11.

@en

A phase II trial of 1st-line m ...... ng RAS mutation: JACCRO CC-11.

@nl

type

Item

label

A phase II trial of 1st-line m ...... ng RAS mutation: JACCRO CC-11.

@en

A phase II trial of 1st-line m ...... ng RAS mutation: JACCRO CC-11.

@nl

prefLabel

A phase II trial of 1st-line m ...... ng RAS mutation: JACCRO CC-11.

@en

A phase II trial of 1st-line m ...... ng RAS mutation: JACCRO CC-11.

@nl

P1476

A phase II trial of 1st-line m ...... ng RAS mutation: JACCRO CC-11.

@en

P2093

Akinori Takagane

http://www.w3.org/2001/XMLSchema#string

Akitaka Makiyama

http://www.w3.org/2001/XMLSchema#string

Hironaga Satake

http://www.w3.org/2001/XMLSchema#string

Hiroshi Nakayama

http://www.w3.org/2001/XMLSchema#string

Kazuma Kobayashi

http://www.w3.org/2001/XMLSchema#string

Manabu Shiozawa

http://www.w3.org/2001/XMLSchema#string

Masahiro Gotoh

http://www.w3.org/2001/XMLSchema#string

Masahiro Takeuchi

http://www.w3.org/2001/XMLSchema#string

Masahito Kotaka

http://www.w3.org/2001/XMLSchema#string

Masashi Fujii

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer.

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC).

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.

Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.

First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.

A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.

P304

18811-18820

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24702

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29721163

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

bevacizumab

phase II clinical trial

P932

5922357

http://www.w3.org/2001/XMLSchema#string